|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 222 West State Street |
Address2 | Suite 302 |
City | Trenton |
State | NJ |
Zip Code | 08608 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 75251-12
|
||||||||
|
6. House ID# 360350000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Steve Issenman |
Date | 1/18/2024 6:13:35 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Promoting awareness of the biopharmaceutical and medical technology sectors.
Opposing the imposition of price controls in the Medicare Part D program.
Generally supporting intellectual property rights.
Opposing various legislative and executive efforts to impose an international price index.
Promoting awareness of increasing antimicrobial/antifungal resistance.
Supporting the PASTEUR Act S. 1355 and H.R. 2940.
Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916).
Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes.
Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET.
Opposing WHO TRIPS waivers.
Supporting the extension of the SBIR program.
Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000).
Supporting changes to the small molecule portions of the Inflation Reduction Act.
Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369).
Opposing proposed FTC changes to non-compete clauses.
Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350).
Generally supporting changes to the 340B program.
Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients.
Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access.
Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations.
Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).
Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing.
Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway.
Opposing the SMART Act (S. 1246).
Supporting the ORPHAN CURES Act (H.R. 5539).
Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764).
Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Environmental Protection Agency (EPA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dean |
Paranicas |
|
|
|
Steve |
Issenman |
|
Cong. Page (87-88), Congressional Aide (1990's) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |